Arvinas Q2 net loss $66.6M; vepdegestrant Phase 3 trials continue; ARV-766 shows 42% PSA50

ARVINAS, INC.

2023-Q2 EPS reported -$2.78 revenue$87,000,000

Net loss $66.6M vs $70.0M YoY; revenue $54.5M (up from $33.8M) from collaboration agreements.
Cash & securities $1,044.3M; expected to fund operations into 2026.
VERITAC-2 (2L) and VERITAC-3 (1L) Phase 3 trials of vepdegestrant enrolling; first Phase 3 data expected 2H 2024.
ARV-766 interim data: 42% PSA50 in AR LBD-mutant mCRPC patients; well-tolerated.
John Houston named Chairperson; Sunil Agarwal appointed to Board; cash runway into 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

ARVINAS, INC. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Arvinas, Inc. announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-23-000075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.